Macular Edema Due to Type 2 Diabetes Mellitus
Conditions
Keywords
Macular Edema
Brief summary
The goal of this clinical trial is to clarify the efficacy of anti-vascular endothelial growth factor (anti-VEGF) drugs combined with subthreshold micropulse laser (SML) therapy on retinal function and anatomical recovery in patients with diabetic macular edema (DME). The main questions it aims to answer are: * To clarify the efficacy of anti-VEGF drugs combined with SML therapy on retinal function and anatomical recovery in DME patients. * To explore the changes in visual acuity and optical coherence tomography angiography (OCTA) parameters before and after the treatment of DME with anti-VEGF drugs combined with SML, and further explore the changes in morphological characteristics of retinal microvessels and the potential treatment mechanism. Participants will randomly be given Intravitreous injection of anti-VEGF drugs or anti-VEGF drugs combined with SML therapy. All participants will be followed up for 6 months after treatment.
Interventions
DRUGAnti-VEGF
Intravitreous injection of anti-VEGF drugs
RADIATIONsubthreshold micropulse laser
577nm micropulse laser photocoagulation therapy
Sponsors
Second Affiliated Hospital, School of Medicine, Zhejiang University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients with non-proliferative diabetic retinopathy (NPDR) meeting diagnostic criteria: the diagnosis can be made by fundus examination, fluorescein fundus angiography (FFA) and optical coherence tomography (OCT), which meet the clinical significant macular edema (CSME) definition criteria, i.e. hard exudation within 500μm of macular fovea with adjacent retinal thickening or edema within 500μm of macular fovea. Or the thickened area of the retina was \> 1 disc diameter (D) and within 1 day of the fovea of the macula. * OCT examination showed a thickened CMT (≥200μm) without hyperplasia or scar * Standard logarithmic visual acuity charts measure the BCVA (LogMAR) range from 0.01 to 1.0 * Control of glycosylated hemoglobin (HbA1c) ≤10% during follow-up * Patients voluntarily participate and sign informed consent
Exclusion criteria
* Patients with severe corneal opacity, cataract and vitreous hemorrhage were found to be affected by OCTA examination by ophthalmic examination. * Patients with other eye diseases or other complications during follow-up, such as glaucoma (IOP\>21mmHg), high myopia (≥-6.0D), and other fundus lesions, such as retinal detachment, vitreous macular traction, preretinal membrane, ischemic macular disease, optic neuritis and other diseases involving the retina and optic nerve. * Patients who have previously received intraocular surgery, vitreous macular traction syndrome, proliferative diabetic retinopathy (PDR) resulting in vitreous hemorrhage or local retinal detachment requiring surgical treatment, and patients with a history of eye trauma. * History of panretinal photocoagulation within 6 months prior to treatment or local/grille photocoagulation within 3 months prior to treatment. * History of intravitreal injection of any steroid within 6 months prior to treatment. * Patients with serious systemic diseases, such as cardiovascular and cerebrovascular diseases or hematopoietic system, patients who have undergone intracranial surgery or intracranial space-occupying lesions, and patients with mental disorders. * Can not cooperate with the ophthalmic examination or other reasons can not obtain the ideal OCTA image. * Pregnant, pregnant or lactating women and patients allergic to drugs. * Suspected or confirmed history of alcohol and drug abuse. * Patients who are participating in clinical trials of other drugs. If one of the above meets and can be excluded.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| central macular thickness (CMT) | up to 6 months | CMT |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| best-corrected visual acuity (BCVA) | up to 6 months | BCVA |
| superficial capillary vessel density (SVD) | up to 6 months | The vessel density of the superficial capillary plexus level will be analyzed in the 3×3 mm OCTA scanning mode. |
| deep capillary vessel density (DVD) | up to 6 months | The vessel density of the deep capillary plexus level will be analyzed in the 3×3 mm OCTA scanning mode. |
| foveal avascular zone (FAZ) | up to 6 months | The area of FAZ will be evaluated on 3×3 mm OCTA image. |
| nonperfusion (NP) | up to 6 months | The NP regions in the superficial and deep capillary plexuswere will be evaluated on the 3×3 mm OCTA Image by Image J software. The scores were as follows: 1 for 0\ 3 NP regions, 2 for 4\ 6 NP regions, and 3 for more than 6 NP regions. |
Countries
China
Contacts
Primary ContactZhiyong Zhang, MD. PhD.
Outcome results
None listed